At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
LYRA Lyra Therapeutics
Pre-Mkt 12-23 06:05:51 EST
3.62
+0.02
+0.56%
High3.74Low3.60Vol23.94K
Open3.63D1 Closing3.60Amplitude3.99%
Mkt Cap6.43MTradable Cap4.79MTotal Shares1.77M
T/O87.34KT/O Rate1.81%Tradable Shares1.32M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Perceptive Advisors LLC Disposes of Lyra Therapeutics Inc. Common Shares
Reuters  ·  11-14
Perceptive Advisors LLC Disposes of Lyra Therapeutics Inc. Common Shares
Lyra Therapeutics Q3 EPS $(3.38) Beats $(5.25) Estimate, Sales $25.000K Miss $195.000K Estimate
Benzinga  ·  11-13
Lyra Therapeutics Q3 EPS $(3.38) Beats $(5.25) Estimate, Sales $25.000K Miss $195.000K Estimate
Lyra Therapeutics Q3 net loss narrows
Reuters  ·  11-13
Lyra Therapeutics Q3 net loss narrows
Lyra Therapeutics Inc Q3 Net Loss per Share $3.38
THOMSON REUTERS  ·  11-13
Lyra Therapeutics Inc Q3 Net Loss per Share $3.38
Perceptive Advisors LLC Reports Sale of Lyra Therapeutics Inc. Common Shares
Reuters  ·  11-11
Perceptive Advisors LLC Reports Sale of Lyra Therapeutics Inc. Common Shares
Lyra Therapeutics Inc expected to post a loss of $5.25 a share - Earnings Preview
Reuters  ·  11-07
Lyra Therapeutics Inc expected to post a loss of $5.25 a share - Earnings Preview
William Blair Keeps Their Hold Rating on Lyra Therapeutics (LYRA)
TIPRANKS  ·  10-14
William Blair Keeps Their Hold Rating on Lyra Therapeutics (LYRA)
Lyra Therapeutics Inc - Enlighten 2 Trial Meets Primary Endpoint in Crs Symptoms
THOMSON REUTERS  ·  10-06
Lyra Therapeutics Inc - Enlighten 2 Trial Meets Primary Endpoint in Crs Symptoms
Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study
GlobeNewswire  ·  10-06
Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study
Lyra Therapeutics Inc. Unveils Presentation on Innovative Sinonasal Drug Implants for Chronic Rhinosinusitis Treatment
Reuters  ·  09-04
Lyra Therapeutics Inc. Unveils Presentation on Innovative Sinonasal Drug Implants for Chronic Rhinosinusitis Treatment
Lyra Therapeutics Receives Nasdaq Deficiency Notice for Failing to Meet Stockholders' Equity Requirement
Reuters  ·  08-23
Lyra Therapeutics Receives Nasdaq Deficiency Notice for Failing to Meet Stockholders' Equity Requirement
U.S. RESEARCH ROUNDUP-ANI Pharmaceuticals, Berkshire Hathaway, Chevron
Reuters  ·  08-18
U.S. RESEARCH ROUNDUP-ANI Pharmaceuticals, Berkshire Hathaway, Chevron
Lyra Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Reuters  ·  08-13
Lyra Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Lyra Therapeutics Inc. Unveils Presentation on Innovative Sinonasal Drug Implants for Chronic Rhinosinusitis Treatment
Reuters  ·  08-13
Lyra Therapeutics Inc. Unveils Presentation on Innovative Sinonasal Drug Implants for Chronic Rhinosinusitis Treatment
Lyra Therapeutics Inc - Financing Extends Cash Runway Into 3Q 2026
THOMSON REUTERS  ·  08-13
Lyra Therapeutics Inc - Financing Extends Cash Runway Into 3Q 2026
Lyra Therapeutics Inc expected to post a loss of $6.02 a share - Earnings Preview
Reuters  ·  08-08
Lyra Therapeutics Inc expected to post a loss of $6.02 a share - Earnings Preview
Lyra Therapeutics Inc - Maria Palasis Appointed Chair of Lyra Board - SEC Filing
THOMSON REUTERS  ·  08-02
Lyra Therapeutics Inc - Maria Palasis Appointed Chair of Lyra Board - SEC Filing
Lyra Therapeutics Inc - Terminates Executive Chairman Harlan Waksal - SEC Filing
THOMSON REUTERS  ·  08-02
Lyra Therapeutics Inc - Terminates Executive Chairman Harlan Waksal - SEC Filing
Lyra Therapeutics Appoints Maria Palasis as Chair of the Board Following Departure of Executive Chairman Harlan Waksal
Reuters  ·  08-02
Lyra Therapeutics Appoints Maria Palasis as Chair of the Board Following Departure of Executive Chairman Harlan Waksal
Lyra Therapeutics Inc. CFO Jason Cavalier Reports Disposal of Common Shares
Reuters  ·  07-15
Lyra Therapeutics Inc. CFO Jason Cavalier Reports Disposal of Common Shares